Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline Portfolio News / By admin March 12, 2020 Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline Read More »
Gritstone Oncology Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights Portfolio News / By admin March 11, 2020 Gritstone Oncology Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights Read More »
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results Portfolio News / By admin March 10, 2020 Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results Read More »
Revolution Medicines’ New Clinical Trial Exploring Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute Portfolio News / By admin March 9, 2020 Revolution Medicines’ New Clinical Trial Exploring Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute Read More »
Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company Portfolio News / By admin March 9, 2020 Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company Read More »
Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Portfolio News / By admin March 5, 2020 Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Read More »
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo Portfolio News / By admin February 24, 2020 NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo Read More »
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By admin February 18, 2020 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More »
Revolution Medicines Announces Pricing of Initial Public Offering Portfolio News / By admin February 12, 2020 Revolution Medicines Announces Pricing of Initial Public Offering Read More »
NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS) Portfolio News / By admin February 11, 2020 NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS) Read More »
